AgingResearch.NewsJoin free

Fesoterodine

Fesoterodine has been studied in 7 papers since 2021: 1 trial and 6 observational studies in people; 1 in the past year. The newest story, Nov 6, 2026: “Bladder drugs presumed safer not linked to lower dementia risk”.

Intervention

7 papers study it4 more mention it6 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 11 papers on fesoterodine

At a glance

The findings reach people, from one lab or study. 3 independent labs in 2 countries; 3 trials, 1 about aging, 1 with no results posted.

“urinary symptom severity and health-related quality of life subscale scores of the Overactive Bladder Questionnaire improved significantly (-22.3±24 and 17.5±19.7, respectively; P < 0.0001)”
Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive BladderFemale pelvic medicine & reconstructive surgery2021doi:10.1097/spv.0000000000001046

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

About aging: the drug’s trials about aging. The total counts its trials for every use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 3 independent labs in 2 countries
  • 3 trials, 1 about aging, 1 with no results posted
  • Funders: National Institute on Aging and 5 more
  • 3 of 3 trials sponsored by its developers
  • Human trial1
  • Humans6

Studies in people

1 study gave fesoterodine to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on cognitive function

Randomized trial1 week23 peopleBothover the Age of 75 YearsThe oldest old; Older adults; mild cognitive impairment and overactive bladderEuropean urology focus, Feb 23, 2024

What did studies of fesoterodine find?

5

Studies of fesoterodine measured 5 outcomes; the most studied are cognitive function (1 study), physical function (1) and sedentary behavior (1).

Cognitive function

no changein humans1

1 study

  1. Fesoterodine showed no clear effect on cognitive function in humans (mild cognitive impairment and overactive bladder).

    “Exposure to steady-state dosing of fesoterodine 4 and 8 mg or oxybutynin 5 mg b.i.d. was not associated with any detectable effect on cognitive function”

    Human trialmild cognitive impairment and overactive bladder4 and 8 mg1 weekn = 23

    A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age of 75 Years with Mild Cognitive Impairment

    European urology focus

Physical function

no changein humans1

1 study

  1. Fesoterodine showed no clear effect on physical function in humans (overactive bladder) (-0.3±2.3, P = 0.6).

    “There was no significant change in the Short Physical Performance Battery score (-0.3±2.3, P = 0.6)”

    Human trialoveractive bladder8 weeksfemalesn = 75

    Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive Bladder

    Female pelvic medicine & reconstructive surgery

Sedentary behavior

upin humans1

1 study

  1. Fesoterodine increases sedentary behavior in humans (overactive bladder) (36.6±88 minutes, P < 0.001).

    “daily sedentary time increased by 36.6±88 minutes (P < 0.001)”

    Human trialoveractive bladder8 weeksfemalesn = 75

    Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive Bladder

    Female pelvic medicine & reconstructive surgery

Daily steps

downin humans1

1 study

  1. Fesoterodine decreases daily steps in humans (overactive bladder) (-420.2±949, P < 0.001).

    “daily steps decreased significantly (-420.2±949, P < 0.001)”

    Human trialoveractive bladder8 weeksfemalesn = 75

    Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive Bladder

    Female pelvic medicine & reconstructive surgery

Urinary symptom severity

downin humans1

1 study

  1. Fesoterodine decreases urinary symptom severity in humans (overactive bladder) (-22.3±24, P < 0.0001).

    “urinary symptom severity and health-related quality of life subscale scores of the Overactive Bladder Questionnaire improved significantly (-22.3±24 and 17.5±19.7, respectively; P < 0.0001)”

    Human trialoveractive bladder8 weeksfemalesn = 75

    Short-Term Effect of Fesoterodine on Physical Function Relevant to Fall Risk in Older Women With Overactive Bladder

    Female pelvic medicine & reconstructive surgery

What is fesoterodine linked with?

1

Studies link fesoterodine with 1 measure, most often dementia (1 study).

Dementia

upin humans1OR 1.39

1 study

  1. Fesoterodine is linked with a higher risk of dementia in humans (compared with mirabegron) (OR 1.39; 95% CI 1.14-1.71).

    “receipt of solifenacin (OR 1.34; 95% CI 1.11-1.60), darifenacin (OR 1.49; 95% CI 1.19-1.86), tolterodine (OR 1.21; 95% CI 1.02-1.45), and fesoterodine (OR 1.39; 95% CI 1.14-1.71) was associated with increased odds of incident dementia”

    Humanscompared with mirabegron6 mo to 1 yr prior to diagnosis

    Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study

    European urology focus

More on Dementia

Has fesoterodine been tested in people?

1 of 3 about aging

Yes: 1 trial and 6 observational studies in people have been published.

About aging

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
JAMA Network Open

Bladder drugs presumed safer not linked to lower dementia risk

Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.Estimated 10-year dementia risk was 20.0% with mirabegron or vibegron, compared with 18.1% with drugs classified as high-risk anticholinergics.

Cohort · 830,393 peopleIncident dementia
Paper

See all 11 papers on fesoterodine

Related